{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:43Z","timestamp":1794018583498,"version":"4.8.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>We present a phase I\/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody in relapsed\/refractory multiple myeloma (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Phase II eligible patients had RRMM that either progressed on\/after \u2265three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI\/IMiD\/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a \u2265very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving \u2265complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving \u2265CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.24.01008","type":"journal-article","created":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T06:10:33Z","timestamp":1718518233000},"page":"2702-2712","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":209,"title":["Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03761108","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Naresh","family":"Bumma","sequence":"first","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Centre, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"University of Miami Health System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-2795","authenticated-orcid":false,"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maly","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Namburi","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-9750","authenticated-orcid":false,"given":"Matthew J.","family":"Pianko","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-978X","authenticated-orcid":false,"given":"Ka Lung","family":"Wu","sequence":"additional","affiliation":[{"name":"Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-1523","authenticated-orcid":false,"given":"Rebecca","family":"Silbermann","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health &amp; Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain (UCLouvain), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-8796","authenticated-orcid":false,"given":"Markus","family":"Munder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":false,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-Lopez","sequence":"additional","affiliation":[{"name":"Hospital 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-3507","authenticated-orcid":false,"given":"Kaniel","family":"Cassady","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"DeVeaux","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruti","family":"Chokshi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Boyapati","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Hazra","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Andres","family":"Sirulnik","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yariv","family":"Houvras","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0834-9"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021860"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1160192"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736"},{"key":"e_1_3_8_23_2","volume-title":"Reforming the Dose Optimization and Dose Selection Paradigm in Oncology","author":"US Food and Drug Administration","year":"2023","unstructured":"US Food and Drug Administration: Project optimus, in Oncology Center of Excellence (ed): Reforming the Dose Optimization and Dose Selection Paradigm in Oncology, 2023. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00371"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"}],"updated-by":[{"DOI":"10.1200\/jco-24-02169","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.01008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:59:09Z","timestamp":1729007949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.01008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1200\/JCO.24.01008"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.01008","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}